Clinical Trial

Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Study acronym: OxyPLEASURE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-29; most recent amendment 2025-09-29.
Status change: Not Yet Recruiting → Recruiting 2025-09-29
Trial Details
NCT Number NCT06808516
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency
Enrollment 42 participants
Start Date 2025-07-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-03